CD8A and neoplasm: TEG011_CD8α-treated mice had a significantly lower tumor burden over time compared to the mock control TEGLM1_CD8α and TEG011-treated groups (Figure 2B), indicating superior tumor control in vivo by TEG011_CD8α.